Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02130687 · ClinicalTrials.gov registry record · NA
Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure
A NA study, sponsored by Vanderbilt University.
- Completed
- Registry status
- NA
- Development phase
- 106
- Enrollment target
NCT02130687: Completed NA study, sponsored by Vanderbilt University.
NCT02130687 is a NA study that has completed, run by Vanderbilt University. The registered enrollment target is 106 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02130687, a NA study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- NA
- Development phase
- 106 participants
- Enrollment target
Study Summary
In this study the investigators will test the hypothesis that dipeptidyl peptidase IV (DPP4) inhibition attenuates the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibition but not angiotensin receptor blockade or calcium channel blockade. The investigators further hypothesize that this effect is mediated by substance P.
Primary Outcome
The primary analyses will focus on mean arterial blood pressure, heart rate, and norepinephrine (NE) concentrations during ramipril versus ramipril+sitagliptin, and during ramipril+sitagliptin versus ramipril+sitagliptin+aprepitant. We will make similar comparisons within the valsartan- and placebo-treated groups. In addition, we will compare blood pressure and heart rate parameters among the ramipril-treated, valsartan-treated, and placebo-treated groups during comparable concurrent treatment.
Interventions
- DRUG Placebo
- DRUG Sitagliptin
- DRUG Aprepitant
- OTHER Mixed Meal Test (MMT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2014-06 |
| Est. Completion | 2020-08 |
| Phase | NA |
What the finished NCT02130687 record still lists
NCT02130687 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02130687 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02130687 about?
NCT02130687 is a clinical study titled "Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure". In this study the investigators will test the hypothesis that dipeptidyl peptidase IV (DPP4) inhibition attenuates the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibition but not angiotensin receptor blockade or calcium channel blockade. The investigators further hypothesize th...
What is the current status of trial NCT02130687?
This trial is currently completed. It is a NA study. The enrollment target is 106 participants. The study started on 2014-06. Estimated completion is 2020-08.
What interventions are being tested in trial NCT02130687?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG), Aprepitant (DRUG), Mixed Meal Test (MMT) (OTHER).
Who is sponsoring clinical trial NCT02130687?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02130687's enrollment target sits among peer trials
106 830th of 2000 higher than 1,167 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia